CANCER DIGEST – Mar. 17, 2018 – The Centers for Medicare & Medicaid Services (CMS) announced on Mar. 16 that Medicare will cover genetic testing needed to match cancer patients with targeted immunotherapies. Specifically Medicare will cover Next Generation Sequencing (NGS) for patients with advanced cancer that has spread or has relapsed or fails to respond to other therapies.
Saturday, March 17, 2018
Saturday, March 10, 2018
UK’s National Health Service to trial mpMRI for prostate cancer
Patient being positioned for an MRI – image used under Creative Commons share alike license from Wikipedia |
Subscribe to:
Posts (Atom)